Holding(s) in Company

RNS Number:0091S
Pharmagene PLC
12 November 2003

                                  SCHEDULE 10

                   NOTIFICATION OF MAJOR INTERESTS IN SHARES



1. Name of company


            Pharmagene plc



2. Name of shareholder having a major interest


            Aberforth Smaller Companies Trust plc



3. Please state whether notification indicates that it is in respect of holding
of the shareholder named in 2 above or in respect of a non-beneficial interest
or in the case of an individual holder if it is a holding of that person's
spouse or children under the age of 18


            As 2 above



4. Name of the registered holder(s) and, if more than one holder, the number of
shares held by each of them




            Clydesdale Bank (Head Office) Nominees Ltd A/C ABERFIT1





5. Number of shares / amount of stock acquired


            Not notified



6. Percentage of issued class


            Not notified



7. Number of shares / amount of stock disposed


            -



8. Percentage of issued class


            -






9. Class of security


            Ordinary shares of 5p each



10. Date of transaction


            Not notified



11. Date company informed


            12 November 2003



12. Total holding following this notification


            4,000,700



13. Total percentage holding of issued class following this notification


            7.61%



14. Any additional information


            Disclosure from Aberforth Smaller Companies Trust plc states the 
            holding referred to in 12 above forms part of the interest of 
            Aberforth Partners which, at present, totals 9,705,876 shares 
            (18.46%)




15. Name of contact and telephone number for queries


            Melanie Pluck                        Tel: [phone]



16. Name and signature of authorised company official responsible for making
this notification


            John Murphy, Company Secretary



Date of notification


            12 November 2003



The FSA does not give any express or implied warranty as to the accuracy of this
document or material and does not accept any liability for error or omission.
The FSA is not liable for any damages (including, without limitation, damages
for loss of business or loss of profits) arising in contract, tort or otherwise
from the use of or inability to use this document, or any material contained in
it, or from any action or decision taken as a result of using this document or
any such material.


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

HOLDLLFFXFBLFBZ